BioSpace News Archive

Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2020.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that Sarah Boyce , President and Chief Executive Officer, and Art Levin , Ph.D., Chief Scientific Officer, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday,

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will participate in a fireside chat at SVB Leerink’s 10 th Annual Global Healthcare Conference

Conference call scheduled for 4:30 p.m. ET today - Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Continues to Enroll - Phase 1 Trial Evaluating VK0214 Ongoing; Expect to Initiate Proof-of-Concept Trial in X-ALD Patients Mid-2021 - Balance Sheet Remains Strong; Year-End Cash Approximately $250 Million

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Leerink 10 th Annual Global Healthcare Conference. Bruce Cozadd , chairman and chief executive officer, will provide an overview of the company and a business and financial update on Wednesday, February 24, 2021

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Kolosis BIO, LLC (Kolosis) announced today, in collaboration with MTF Biologics (MTF), the market release of Kore Fiber™, an exclusively processed demineralized cortical fiber allograft for Kolosis.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the closing of its previously announced registered direct offering of 2,246,784 shares of common stock,

Combined public entity to develop and commercialize next-generation immune therapies that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The press release will be followed by a conference call at 5:00 p.m. ET,